Clinical Trials Logo

Sleep Disturbance clinical trials

View clinical trials related to Sleep Disturbance.

Filter by:

NCT ID: NCT03668873 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Telehealth Delivery of Treatment for Sleep Disturbances in Young Children With Autism Spectrum Disorder

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Study Design: Ninety children with Autism Spectrum Disorder (ASD), between the ages of 2 to less than 7 years, and their parents will be recruited for this 10 week randomized clinical trial. Participants will be randomized to five individually delivered sessions of Sleep Parent Training (SPT) or five individually delivered sessions of Sleep Parent Education (SPE). Delivery of the programs will be via telehealth platform which also includes parent-child coaching in real-time. In addition to baseline, outcome measures will be collected at week 5 (midpoint of trial) and week 10 (endpoint of trial) as well as follow-up at week 16 to determine durability of treatment.

NCT ID: NCT03659630 Completed - Clinical trials for Stress, Psychological

MyCompass in a Swedish Context - an Automated Self-help Intervention Targeting Mental Health Problems

Start date: December 2015
Phase: N/A
Study type: Interventional

The study present findings from the implementation of myCompass, a fully automated self-help intervention of Australian origin for mild to moderate anxiety and depression, in a Swedish context. The study also investigates the usage of a specially designed research platform aimed at handling informed consent and online surveys.

NCT ID: NCT03624400 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

Internet-delivered Cognitive Behaviour Therapy for Sleep Problems in ASD

Start date: January 30, 2024
Phase: N/A
Study type: Interventional

This trial investigates the behavioural effects of Internet-based Cognitive behaviour therapy for insomnia (CBT-I) in adolescents with autism spectrum disorder with sleep problems. This is a randomised controlled trial.

NCT ID: NCT03606707 Recruiting - Sleep Disturbance Clinical Trials

Efficacy of Fluoroscopic Guided Atlantoaxial Joint Injection on Head and Neck Pain and Sleep Quality in RA Patients

Start date: June 1, 2018
Phase: Early Phase 1
Study type: Interventional

Efficacy of intra-articular steroid injection for inflamed atlantoaxial joint in patients with rheumatoid arthritis Inclusion criteria Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Exclusion criteria Coagulopathy, allergy to contrast material, pregnancy Interventional group (AS) group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.

NCT ID: NCT03545048 Completed - Knee Osteoarthritis Clinical Trials

Effects of Internet / Web-based Exercises on the Population With Knee Arthritis

Knee OA
Start date: October 15, 2018
Phase: N/A
Study type: Interventional

1. To test whether internet-based exercises reduce the pain in knee OA 2. To check whether internet-based exercises improve the physical activity in the patients with knee OA. 3. To explore the correlation between sleep, knee inflammation (effusion, synovial hypertrophy or/and synovial hyper vascularity) and biomarkers of insulin resistance and knee pain.

NCT ID: NCT03537963 Recruiting - Sleep Disturbance Clinical Trials

Improving Sleep in BMT Survivors

Start date: May 15, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to: To test a new intervention for sleep disturbance among hematopoietic cell transplant survivors. About 60 hematopoietic cell transplant (HCT) survivors will participate in this intervention. Preliminary Steps: To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in hematopoietic cell transplant (HCT) survivors and on preferences for a new mHealth intervention for sleep disturbance. About 30 individuals (10 HCT survivors, 10 caregivers and 5-10 clinicians) will participate in this part of the study.

NCT ID: NCT03490877 Completed - Atopic Dermatitis Clinical Trials

Scratch and Sleep Quantification in Atopic Dermatitis

SQUAD
Start date: July 13, 2018
Phase:
Study type: Observational

Atopic dermatitis (AD) is a chronic type of eczema affecting approximately 10% of adults and 12% of children in the US. The intense itching (pruritus) associated with AD can be significantly disruptive to sleep and quality of life for both the patients and their caregivers. AD is challenging to describe and measure. The purpose of this study is to see if we can reliably measure how much people with AD scratch and how scratching interferes with sleep and quality of life by using digital sensors, sleep studies and patient-reported information.

NCT ID: NCT03415230 Completed - Anxiety Clinical Trials

Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This is a randomized control trial to test the effectiveness of therapeutic massage on the sleep quality and the stress levels in women that have completed their treatment for breast cancer.

NCT ID: NCT03412591 Completed - Sleep Disturbance Clinical Trials

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

Suvsubuse
Start date: July 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Insomnia is an extremely common and poorly treated problem in patients with substance use disorders (SUD)s undergoing rehabilitation treatment in a residential facility. The persistence of insomnia in substance use disorders (SUDs) may be associated with tonic levels of drug craving. Insomnia and craving can predispose to relapse in patients with SUDs. Insomnia and SUDs are independently associated with increased cortisol indicating physiological dysregulation of the stress response system including the hypothalamic-pituitary-adrenal (HPA) axis. Hence sleep disturbance, craving and increased cortisol leads to relapse in SUD subjects. Suvorexant, an orexin 1 / 2 receptor antagonist, approved by the FDA for the treatment of sleep disturbance in subjects with primary Insomnia. Previous animal studies report Orexin 1 receptor antagonist decreases craving and normal the HPA axis. However, the efficacy of suvorexant on sleep and craving in SUD subjects is not known. The primary aims of this study are- 1. To determine if suvorexant will improve sleep quality (increased total sleep time, fewer awakenings), as measured through wrist actigraphy and the Insomnia Severity Index (ISI) in SUDs. 2. To assess whether or not SUDs patients treated with suvorexant endorse scale items on a modified abuse liability assessment battery. 3. To determine if daily reports of mood, stress, craving and sleep using Ecological Momentary Assessment (EMA data) change during the course of the study as patients with SUDs are treated with suvorexant. 4. To determine if patients taking suvorexant will have a decrease in total daily salivary cortisol over the course of the study by collecting samples at five time points in a day, for two consecutive days at two different times in the study.

NCT ID: NCT03380897 Completed - Depression Clinical Trials

Sleep and Depression in Induction of Labour

Start date: June 7, 2017
Phase: N/A
Study type: Interventional

Randomised trial comparing double balloon catheter for induction of labor between inpatient and outpatient groups. The investigators assess how sleep disturbances and depression of the mother affect to the pain during balloon catheter induction of labour.